This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
The sources searched to identify primary studies were not stated.
Criteria used to ensure the validity of primary studies
The criteria used to ensure the validity of primary studies were not stated.
Methods used to judge relevance and validity, and for extracting data
Summary statistics from individual studies were used.
Number of primary studies included
At least 8 studies were included.
Methods of combining primary studies
A narrative method was employed.
Investigation of differences between primary studies
It was not stated whether an investigation of the differences between primary studies had been carried out.
Results of the review
For amiodarone, the probability of mild/moderate neurological impairment was 4.5%. The probabilities of severe neurological impairment, hyperthyroidism, and hypothyroidism were 0.5%, 0.3%, and 2.7%. The probability of mild/moderate ocular impairment was 2%.
The probabilities of mild/moderate pulmonary toxicity, severe pulmonary toxicity, and mild hepatic toxicity were 1.8%, 0.2%, and 0.99%.
The probabilities of severe hepatic toxicity and skin discolouration/photosensitivity were 0.01 and 10%.
The probability of symptomatic bradycardia was 3% in the first 6 months.
For catheter ablation, the probabilities of mild and severe thromboembolic events was 1.35 and 1.35, respectively.
The probabilities of moderate cardiac perforation and mild or moderate heart block were 1.17% and 2.70%, respectively.
